ReviewJournal of nanobiotechnology2026
In vivo CAR-T therapy: from molecular design to precision delivery.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated Engineering of CAR-T Cells for Solid Tumours.Cell proliferation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In 2017, the United States Food and Drug Administration (FDA) granted the inaugural approval of chimeric antigen receptor T cell (CAR-T) therapy, marking the advent of a new era in cancer immunotherapy. However, the conventional ex vivo CAR‑T cell manufacturing workflow is complex and time consuming, resulting not only in high treatment costs and limited patient access, but also in effector differentiation of T cells and upregulation of exhaustion markers during prolonged in vitro expansion, which may impair the durability and antitumor activity of the cell product and reduce therapeutic efficacy. To enhance the efficacy and accessibility of CAR-T therapy, the strategy of in vivo generation of CAR cells has emerged as a prominent research focus, notwithstanding substantial technical challenges and its broad prospects. This review systematically summarizes the latest advances, technical challenges, and future trends of in vivo CAR-T therapy, with an emphasis on CAR mRNA molecular design, structural modifications, advancements in gene delivery technologies, and clinical applications, aiming to provide a comprehensive reference for related research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.